Treating AI as a technology initiative delegated to IT is a critical error. Given its transformative impact on competitive advantage, risk, and governance, AI strategy must be owned and overseen by the board of directors. Board ignorance of AI initiatives creates significant, potentially company-ending, corporate risk.
Many pharma companies have breakthrough AI results in isolated functions, or "pockets of excellence." However, the ultimate competitive advantage will go to the company that first connects these disparate successes into a single, integrated, enterprise-wide AI capability, thereby creating compounded value across the organization.
AI requires significant upfront investment with uncertain returns, creating an "investment paradox" for CFOs. Traditional ROI models are insufficient. A new financial framework is needed that measures not just cost savings but also revenue acceleration, risk mitigation, and the strategic option value of competitive positioning.
Successful AI strategy development begins by asking executives about their primary business challenges, such as R&D costs or time-to-market. Only after identifying these core problems should AI solutions be mapped to them. This ensures AI initiatives are directly tied to tangible value creation.
Companies run numerous disconnected AI pilots in R&D, commercial, and other silos, each with its own metrics. This fragmented approach prevents enterprise-wide impact and disconnects AI investment from C-suite goals like share price or revenue growth. The core problem is strategic, not technical.
The impulse to make all historical data "AI-ready" is a trap that can take years and millions of dollars for little immediate return. A more effective approach is to identify key strategic business goals, determine the specific data needed, and focus data preparation efforts there to achieve faster impact and quick wins.